Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck & Co., Inc
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
Taste Assessment of Maxalt Oral Disintegrating Tablets in Children
To evaluate the palatability of Maxalt-MLT® ODT in pediatric migraineurs, ages 6 - 11 years.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Efficacy and Safety of Ertugliflozin Monotherapy in the Treament of Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise
(1) Objective: At Week 26, to assess the effect on HbA1c of 15 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean reduction from baseline in HbA1c for 15 mg ertugliflozin is...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subjects 60 years of age and older
1. To determine whether ZOSTAVAX™ administered concomitantly with PNEUMOVAX™ 23 elicits a VZV antibody response that is noninferior to that of ZOSTAVAX™ administered nonconcomitantly. 2. To demonst...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Ensayo aleatorizado, de adaptación y con dos partes de ridaforolimus combinado con dalotuzumab en comparación con exemestano o en comparación con ridaforolimus o dalotuzumab en monoterapia en pacientes con cáncer de mama con receptores estrogénicos positivos";"A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients
En la parte A de este estudio, el objetivo principal es evaluar la eficacia de la combinación de ridaforolimus y dalotuzumab en comparación con exemestano mediante el análisis de la supervivencia sin ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
V212 Lot Consistency Study
To determine whether V212 from three consistency lots have similar immunogenicity.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma
To determine the duration of PFS in patients with multiple myeloma, after at least 1 prior treatment regimen, treated with bortezomib and vorinostat compared to patients treated with bortezomib and pl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Newly Diagnosed and Treatment-Naïve Multiple Myeloma
Compare the Progression Free Survival (PFS) as assessed by independent central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process
Main objective : (1a) To demonstrate that at 1 month after the third dose of vaccine, both the modified process vaccine and COMVAX™ will induce adequate seroprotection rates (SPR, % of subjects with...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer
-Evaluate PFS per RECIST 1.1 by blinded independent radiologists’ review of all subjects with recurrent/progressive metastatic urothelial cancer treated with pembrolizumab (MK-3475) compared to paclit...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 5 ans
Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options
This program is designed to provide expanded access to MK-0518 prior to the product’s approval and availability on the market. The safety and tolerability of MK-0518 400 mg b.i.d. for the treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next